Jason Adair

Corporate Officer/Principal bei Liquidia Technologies, Inc.

Vermögen: 1 Mio $ am 30.04.2024

Health Technology

Consumer Services

Aktive Positionen von Jason Adair

Unternehmen	Position	Beginn	Ende
Liquidia Technologies, Inc. Liquidia Technologies, Inc. Pharmaceuticals: MajorHealth Technology Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded by Joseph M. DeSimone, Ashok K. Mendiratta, Edward T. Samulski, William R. Kenan, Ginger Denison and Jason Rolland in 2004 and is headquartered in Morrisville, NC.	Corporate Officer/Principal	14.01.2016	-

Unternehmen	Position	Beginn	Ende
BIOCRYST PHARMACEUTICALS, INC.	Corporate Officer/Principal	01.08.2011	01.12.2015
LIQUIDIA CORPORATION	Investor Relations Kontakt	-	-
	Public Communications Contact	-	-
	Corporate Officer/Principal	-	-

Wake Forest University	Undergraduate Degree
Tuck School of Business at Dartmouth	Masters Business Admin

International

Vereinigte Staaten

Operativ

Corporate Officer/Principal	3
Undergraduate Degree	1
Masters Business Admin	1

Sektoral

Health Technology	4
Consumer Services	3

Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Börsennotierte Unternehmen	2
BIOCRYST PHARMACEUTICALS, INC.	Health Technology
LIQUIDIA CORPORATION	Health Technology

Private Unternehmen	1
Liquidia Technologies, Inc. Liquidia Technologies, Inc. Pharmaceuticals: MajorHealth Technology Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded by Joseph M. DeSimone, Ashok K. Mendiratta, Edward T. Samulski, William R. Kenan, Ginger Denison and Jason Rolland in 2004 and is headquartered in Morrisville, NC.	Health Technology

Private Unternehmen

Health Technology